Lisa Cook sues Trump over firing attempt, emergency hearing set
On May 21, 2025, Sensei Biotherapeutics, Inc. conducted its annual stockholders meeting where three significant proposals were voted upon. With a current market capitalization of $7.55 million and trading at $0.30 per share, the company has seen its stock decline nearly 80% over the past year. The meeting saw a substantial turnout with 65.92% of the outstanding shares represented. The results of the meeting, which are based on a recent SEC filing, are as follows:According to InvestingPro analysis, Sensei maintains a strong liquidity position with a current ratio of 6.82, though the company faces challenges ahead. InvestingPro subscribers have access to 10+ additional key insights about the company’s financial health.
The first proposal was the election of two board directors who will serve until the 2028 annual meeting. William Ringo received 8,909,569 votes in favor and 962,061 withheld, while John Celebi (IS:CLEBI) secured 9,209,162 votes for and 662,468 withheld. Both nominees were successfully elected with a notable number of broker non-votes at 6,746,184 for each candidate.
The second proposal concerned the ratification of Deloitte & Touche LLP as the company’s independent auditor for the fiscal year ending December 31, 2025. The proposal passed with 15,802,127 votes for, 369,929 against, and 445,758 abstentions.
The third and final proposal was to approve an amendment for a reverse stock split at a ratio between 1-for-10 and 1-for-30, at the board’s discretion, along with a corresponding reduction in the total number of authorized shares. This proposal also passed with 14,694,068 votes for, 1,602,413 against, and 321,333 abstentions.
These decisions are pivotal for Sensei Biotherapeutics, a Delaware-incorporated pharmaceutical company, as they reflect shareholder confidence and chart the course for the company’s corporate governance and financial strategy moving forward. The SEC filing provides transparency and ensures that the shareholders’ voices are heard and acted upon in the company’s decision-making process.
In other recent news, Sensei Biotherapeutics has announced preliminary results from its ongoing Phase 1/2 clinical trial for solnerstotug, a promising cancer therapy. The trial, which involves 60 patients with advanced solid tumors, reported a 14% overall response rate in patients resistant to PD-(L)1 inhibitors, a notable achievement given the typical response rates for such patients. Among the significant findings was a durable complete response in a Merkel Cell Carcinoma patient who has been tumor-free for over 42 weeks. Additionally, partial responses were observed in another Merkel Cell Carcinoma patient and a microsatellite instability-high Colorectal Cancer patient. The therapy has been well-tolerated, with most adverse events being mild and manageable.
H.C. Wainwright has reaffirmed its Buy rating on Sensei Biotherapeutics, maintaining a $4 price target, citing these trial results as a basis for their confidence. The firm highlighted the 62% disease control rate and the ongoing response in patients as positive indicators for the therapy’s potential. Sensei Biotherapeutics plans to commence a Phase 2 study in the first quarter of 2026, focusing on biomarker-based patient selection to enhance treatment outcomes. The company is set to host an investor webcast to further discuss these findings and the future direction of the solnerstotug program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.